• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Icatibant
    / Teva

    Active Ingredient
    Icatibant (as acetate) 30 mg / 3 ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Syringe (solution for injection)

    1 X 3 ml

    partial basket chart 30653


    General accepted dosage is: One subcutaneous injection of Icatibant  (3 ml/30 mg), as soon as signs of attack are detected (e.g. swelling of the skin, especially in the area of the face and neck, or increasing abdominal pain).
    If the condition is not improved in 6 hours, another 3 ml dose may be administered.
    If there is still no improvement, a third dose may be administered after another 6 hours.
    No more than 3 doses in 24 hours and no more than 8 injections of Icatibant in one month!
    See prescribing information for full details.


    Treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.


    Hypersensitivity to the active substance or to any of its excipients.

    Special Precautions

    See prescribing information for full details.

    Pregnancy and Lactation

    Pregnancy: The patient should consult the doctor before using this medicine.
    Lactation: The patient should not breastfeed for 12 hours after administration of this medicine.
    See prescribing information for full details.

    Teva Pharmaceutical Industries Ltd, Israel